Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients

Cystic Fibrosis in Children Clinical Trial

Official title:

Effect of Antioxidant Docosahexaenoic Acid (DHA) Supplementation in Cystic Fibrosis Patients: A Randomized Placebo-controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04987567
• Other study ID #: PED-DHA-FQ
• Status: Completed
• Phase: N/A
• Start date: March 21, 2018
• Est. completion date: February 20, 2020

Study information

• Verified date: June 2021
• Source: Corporacion Parc Tauli
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the effect of antioxidant docosahexaenoic acid (DHA) in patients with cystic fibrosis. Half of participants will receive DHA, while the other half will receive placebo.

Description:

Several studies show that patients with cystic fibrosis (CF) usually have, compared to the normal population, low levels of linoleic acid (LA) and docosahexaenoic acid (DHA) and increase in arachidonic acid (AA), which is pro-inflammatory. Normalization or modification of this fatty acid pattern (AP) could reduce chronic inflammation. The aim of this study is to assess the effect of oral supplementation with DHA for one year in pediatric patients (6-18 years) with CF, on inflammatory parameters, AP profile, lung function (spirometry) and number of exacerbations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: February 20, 2020
• Est. primary completion date: February 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

• Patients of both genders with a diagnosis of cystic fibrosis.
• FEV1 > 40%.
• Age between 6 and 18 years.
• Patients who grant their informed consent or whose representative grants informed consent to participate in the study.

Exclusion Criteria:

• Pregnant or breastfeeding women
• Basal oxygen saturation <92% or household supplemental oxygen needs.
• Massive hemoptysis
• Patients who are not able to follow or who cannot be assessed in the study according to the protocol.
• Any circumstance that, at the discretion of the doctor, may involve a clinical risk or harm, the patient's participation in the study or that interferes with the evaluation of the same.
• Use of systemic glucocorticoids or in the 4 weeks prior to inclusion in the study.
• Use of non-steroidal anti-inflammatory drugs in the 2 weeks prior to inclusion in the study.
• Use of investigational drugs or participation in another clinical trial within 30 days prior to inclusion in the study or within the 5 elimination half-lives of the investigational drug.
• Be already supplementing with Omega -3, fish oil or DHA

Related Conditions & MeSH terms

• Cystic Fibrosis
• Cystic Fibrosis in Children
• Fibrosis

Intervention

Dietary Supplement:
• ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)
Pearls of DHA (BrudyNen)
• PLACEBO (OLIVE OIL)
Pearls manufactured to mimic DHA (BrudyNen).

Locations

Country	Name	City	State
Spain	Parc Tauli Hospital	Sabadell	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Fatty Acid (FA) profile (percentage) of the erythrocyte membrane at 6 and 12 months	After blood sampling, erythrocytes are separated from the plasma by centrifugation (2500 rpm for 15 min) and stored at -80ºC until analysed. The fatty acids composition are analyzed by gas chromatography.; Fatty acid composition (SFA (saturated FA), MUFA (monoinsatured FA), PUFAs N-6 (polyunsaturated FA omega-6) and PUFAS N-3) are mesured as percentage of total fats.	baseline, 6 month and 12 month of treatment (end of study)
Secondary	Change from Baseline Serum interleukins at 12 months	Serum are obtained by centrifugation of blood samples and frozen at -80ºC until testing.; Interleukins (IL)-1 ß, IL-6, IL-8 and tumor necrosis factor (TNF)-a (pg/ml) are analized in serum by enzyme-linked immunosorbent assay (ELISA kits).	baseline and 12 month of treatment (end of study)
Secondary	Change from baseline pulmonary function at 3,6 ,9 and 12 months	Forced expiratory volume in 1 second (FEV1) , forced vital capacity (FVC) and 25-75% of the forced vital capacity (FEF25-75%) were mesured using spirometry, calibrated daily according to standardized techniques.; The results are expressed as the mean value of the percentage of predicted values according to height and sex and litres (L)	baseline, 3 months, 6 month, 9 months and 12 month of treatment (end of study)
Secondary	Number of Pulmonary exacerbation during the study year compared with previous years	The investigators will report the number of pulmonary exacerbations during the previous year and the year of the study. To calculate the number of exacerbations, the medical records of the patients will be reviewed.	12 months prior study, 12 months of the study
Secondary	Change from baseline fecal calprotectin at the 12 months	Calprotectin was measured in fecal samples of the participants.	Baseline and 12 months
Secondary	Adverse reactions during the study	Frequency of occurrence of adverse events related to the study treatment: diarrhea, steatorrhea, abdominal pain, nausea, vomiting, gastroesophageal reflux, fishy taste or hemorrhage.	baseline, 3, 6 , 9 and 12 month of treatment (end of study)
Secondary	Change from Baseline Esputum interleukins at 6 and 12 months	Supernatant induced sputum were frozen at -80ºC until testing. Induced sputum Interleukins (IL)-1 ß, IL-6, IL-8 and tumor necrosis factor (TNF)-a (pg/ml) were analized by enzyme-linked immunosorbent assay (ELISA kits).	baseline and 12 months
Secondary	Change from baseline differencial cell counts in sputum at 6 and 12 months.	An equal volume of sterile dithiothreitol (DTT), freshly diluted to 10% by the addition of sterile saline, was added to the sputum. This step was performed under a Bio-safety hood using sterile technique. The samples were then incubated in a shaking water bath at 37° C for 5-10 min, and gently mixed using a transfer pipette at 5-min intervals. The weight of the remaining sputum mixture was measured, and a further three times the volume of both DTT and phosphate-buffered saline (Dulbecco's; Gibco BRL, Grand Island, NY) were added. The mixture was incubated once again in the 37° C shaking water bath for another 5-10 min to ensure complete homogenization. Ten microliters of the homogenized sputum samples, mixed with Trypan Blue stain, was used to calculate total cell counts, using a standard hemacytometer. A further 0.25-0.50 ml of both samples was used to prepare cytospin slides for differential cell counts.	baseline, 6 months and 12 monts
Secondary	Change from baseline weight at 3, 6, 9 and 12 months	Weight in kilograms (kg) were measured every 3 months. Subjects dressed only in light underwear and shoeless.	Baseline, 3,6,9 and 12 months
Secondary	Change from baseline height at 3, 6, 9 and 12 months	Height was measured with a standardised statdiometer every 3months	Baseline, 3,6,9 and 12 months
Secondary	Change from baseline body mass index (BMI) at 3, 6, 9 and 12 months	BMI was calculate every 3 months.	Baseline, 3,6,9 and 12 months
Secondary	Change from Baseline FA ratios of the erythrocyte membrane at 6 and 12 months	The next fatty acids (FA) ratios were calculated: Arachidonic acid /eicosapentaenoic acid (ARA/EPA) Arachidonic acid/ docosahexaenoic acid (ARA/DHA) N-3 PUFAS/ALA ( a-linolenic acid) N-6 PUFAS/LA (linoleic acid)	baseline, 6 months and 12 months